您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > BIM 23042
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BIM 23042
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BIM 23042图片
CAS NO:111857-96-6
包装:1mg
市场价:1985元

产品介绍
Antagonist of neuromedin B receptor,selective
Cas No.111857-96-6
Canonical SMILESCC([C@@](/N=C(O)/[C@](/N=C(O)/[C@@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@@](N)([H])C1=CC2=CC=CC=C2C=C1)([H])CS)([H])CC3=CC=C(O)C=C3)([H])CC4=CNC5=CC=CC=C45)([H])CCCCN)([H])/C(O)=N/[C@@](/C(O)=N/[C@@](C(O)=N)([H])CC6=CC7=CC=CC=C7C=C6)([H])CS)C
分子式C62H73N11O9S2
分子量1180.44
溶解度Soluble to 1 mg/ml in 0.1% acetic acid
储存条件Desiccate at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Ki: 49 ±14 nM for neuromedin B-induced endpoint in huNMBR cells

Neuromedin B, a mammalian peptide of the bombesinlike peptide family sharing amino acid homology with its amphibian counterpart ranatensin, elicits a diverse array of biological responses in central and peripheral tissues. BIM 23042 [D-Nal-Cys-Tyr- D-Trp-Lys-Val-Cys-Nal-NH2] is a selective neuromedin B antagonist.

In vitro: BIM 23042 has a l00-fold greater affinity for BB1 receptors than BB2 receptors. The submaximal mobilisation observed with neuromedin B (1 nM) was abolished by BIM 23042 but restored with a subsequently higher concentration of neuromedin B (1 μM). BIM 23042 competitively inhibited neuromedin B-induced endpoint in huNMBR cells with a Ki of 49 ±14 nM [1].

In vivo: In cat upper GI tract, SSocta, at concentrations of 10 mM, did not influence the smooth muscle tone but shifted NMB concentration response to the right yielding (Ki=1.7±0.8 mM). Ssocta inhibited both NMB- and GRP-induced contractions on the esophagus. the NMB-receptor antagonist SSocta had no effect on circular fundic muscle indicating the absence of this receptor subtype on fundus. [2].

Clinical trial: Up to now, BIM 23042 is still in the preclinical development stage.

References:
[1] Ryan RR, Taylor JE, Daniel JL, Cowan A.  Pharmacological profiles of two bombesin analogues in cells transfected with human neuromedin B receptors. Eur J Pharmacol. 1996 Jun 13;306(1-3):307-14.
[2] Milusheva EA, Kortezova NI, Mizhorkova ZN, Papasova M, Coy DH, Bálint A, Vizi ES, Varga G.  Role of different bombesin receptor subtypes mediating contractile activity in cat upper gastrointestinal tract. Peptides. 1998;19(3):549-56.